In case you were distracted at the end of last week, a major development took place at CMS (Center for Medicare & Medicaid Services) when the decision was made and the agency stated that the Dexcom G5 Mobile was now determined to be classified in a benefit category as therapeutic; thus allowing the agency to cover the device for those people on Medicare or Medicaid.
Dexcom should be applauded for their tireless efforts in this area fighting for the approval of the device. I get it, their stock soared upon the approval and hence, it could be said it was why they battled. Dexcom is a business. And in the world of diabetes, businesses that are run correctly, deserve whatever they are allowed.
Kevin Sayer, President and CEO, has run his Dexcom Company with diligence, integrity, they give back to the community, and if they benefit for fighting so hard so everyone wanting their CGM, even those on social services and not on commercial insurance, can get one…..more power to them. Not to mention those turning 65 will now no longer lose their coverage for a CGM for merely getting older.
It’s no wonder that Dexcom seems to constantly show the business world of diabetes why their business objectives and business platform are second to none. The diabetes community can only hope others take note and follow their lead.
You can read Dexcom’s press release by clicking here.
I am a DiabetesDad.
Please visit my Diabetes Dad FB Page and hit ‘like’